JPWO2022059780A1 - - Google Patents

Info

Publication number
JPWO2022059780A1
JPWO2022059780A1 JP2022550632A JP2022550632A JPWO2022059780A1 JP WO2022059780 A1 JPWO2022059780 A1 JP WO2022059780A1 JP 2022550632 A JP2022550632 A JP 2022550632A JP 2022550632 A JP2022550632 A JP 2022550632A JP WO2022059780 A1 JPWO2022059780 A1 JP WO2022059780A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022550632A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022059780A1 publication Critical patent/JPWO2022059780A1/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022550632A 2020-09-18 2021-09-17 Pending JPWO2022059780A1 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020156848 2020-09-18
JP2021070531 2021-04-19
PCT/JP2021/034333 WO2022059780A1 (ja) 2020-09-18 2021-09-17 iPS細胞を介する再生T細胞の製造方法

Publications (1)

Publication Number Publication Date
JPWO2022059780A1 true JPWO2022059780A1 (cg-RX-API-DMAC7.html) 2022-03-24

Family

ID=80776150

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022550632A Pending JPWO2022059780A1 (cg-RX-API-DMAC7.html) 2020-09-18 2021-09-17

Country Status (5)

Country Link
US (1) US20230183645A1 (cg-RX-API-DMAC7.html)
EP (1) EP4215604A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022059780A1 (cg-RX-API-DMAC7.html)
CN (1) CN115698270A (cg-RX-API-DMAC7.html)
WO (1) WO2022059780A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3822342A4 (en) * 2018-07-13 2022-08-03 Kyoto University METHOD OF PRODUCTION OF GAMMA DELTA T-CELLS
CA3213440A1 (en) * 2021-04-16 2022-10-20 Thyas Co. Ltd. A cell bank composed of ips cells for transfecting t cell receptor gene
JPWO2023249071A1 (cg-RX-API-DMAC7.html) * 2022-06-24 2023-12-28

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011096482A1 (ja) * 2010-02-03 2011-08-11 国立大学法人東京大学 多能性幹細胞を用いた免疫機能再建法
WO2016010154A1 (ja) * 2014-07-18 2016-01-21 宏 河本 抗原特異的t細胞受容体遺伝子を有する多能性幹細胞の製造方法
JP2018512380A (ja) * 2015-03-13 2018-05-17 サイズ セル セラピー コーポレイション 活性化t細胞を用いるがん治療の方法
WO2018143454A1 (ja) * 2017-02-06 2018-08-09 国立研究開発法人国立がん研究センター 新規t細胞受容体
WO2020022512A1 (ja) * 2018-07-26 2020-01-30 国立大学法人京都大学 外来抗原レセプター遺伝子導入細胞の製造方法
WO2020027094A1 (ja) * 2018-07-31 2020-02-06 サイアス株式会社 iPS細胞を介して再生T細胞集団を製造する方法
WO2021106832A1 (ja) * 2019-11-25 2021-06-03 国立大学法人京都大学 T細胞マスターセルバンク

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105925535A (zh) * 2009-06-05 2016-09-07 细胞动力国际有限公司 重编程t细胞和造血细胞的方法
JP5963309B2 (ja) * 2010-11-09 2016-08-03 国立研究開発法人産業技術総合研究所 末梢血単球由来多能性幹細胞作製方法
EP2853590B1 (en) * 2012-05-22 2018-11-07 The University of Tokyo Method for producing antigen-specific t cells
AU2015290554A1 (en) * 2014-07-18 2017-03-09 Kyoto University Method for inducing T cells for cell-based immunotherapy from pluripotent stem cells
KR102946326B1 (ko) * 2017-09-05 2026-03-31 시애틀 프로젝트 코포레이션 T-세포 요법을 위한 신생항원 동정
US20200345789A1 (en) * 2017-10-06 2020-11-05 Thyas, Co. Ltd. Production method for ips cell-derived population of genetically diverse t cells
EP3822342A4 (en) * 2018-07-13 2022-08-03 Kyoto University METHOD OF PRODUCTION OF GAMMA DELTA T-CELLS
US20210040558A1 (en) * 2019-07-15 2021-02-11 Neogene Therapeutics B.V. Method to isolate tcr genes
GB201911953D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd T cell production fram RAG inacivated iPSCs
EP4273234A4 (en) * 2021-01-04 2025-04-23 Thyas Co. Ltd. Method for producing a regenerated T cell via an IPS cell
CA3213440A1 (en) * 2021-04-16 2022-10-20 Thyas Co. Ltd. A cell bank composed of ips cells for transfecting t cell receptor gene

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011096482A1 (ja) * 2010-02-03 2011-08-11 国立大学法人東京大学 多能性幹細胞を用いた免疫機能再建法
WO2016010154A1 (ja) * 2014-07-18 2016-01-21 宏 河本 抗原特異的t細胞受容体遺伝子を有する多能性幹細胞の製造方法
JP2018512380A (ja) * 2015-03-13 2018-05-17 サイズ セル セラピー コーポレイション 活性化t細胞を用いるがん治療の方法
WO2018143454A1 (ja) * 2017-02-06 2018-08-09 国立研究開発法人国立がん研究センター 新規t細胞受容体
WO2020022512A1 (ja) * 2018-07-26 2020-01-30 国立大学法人京都大学 外来抗原レセプター遺伝子導入細胞の製造方法
WO2020027094A1 (ja) * 2018-07-31 2020-02-06 サイアス株式会社 iPS細胞を介して再生T細胞集団を製造する方法
WO2021106832A1 (ja) * 2019-11-25 2021-06-03 国立大学法人京都大学 T細胞マスターセルバンク

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ICH HARMONISED TRIPARTITE GUIDELINE, vol. Current Step 4 version, JPN6026027490, 1997, pages 1 - 13, ISSN: 0005901433 *

Also Published As

Publication number Publication date
EP4215604A1 (en) 2023-07-26
US20230183645A1 (en) 2023-06-15
WO2022059780A1 (ja) 2022-03-24
CN115698270A (zh) 2023-02-03
EP4215604A4 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
JPWO2022220146A1 (cg-RX-API-DMAC7.html)
CN306643977S (zh) 餐叉(坠纹)
CN306462394S (zh) 儿童助载车车身(宝马m5)
CN305579649S (zh) 酒瓶(五粮贵宾-套装181)
CN305578553S (zh) 茶几(gncj01)
CN305606738S (zh) 电竞椅扶手
CN305572882S (zh) 保鲜碗
CN305582510S (zh) 加湿器(复古)
CN305541842S (zh) 电磁炉(816)
CN305577334S (zh) 眼线笔
CN305581682S (zh) 抛光机
CN305564025S (zh) 椅子(轮胎)
CN305532555S (zh) 灯饰配件(多样化新式面包灯)
CN305574673S (zh) 柴油雾化喷射器
CN305554443S (zh) 桌面净化器
CN305567329S (zh) 电动自行车(6)
CN305533451S (zh) 教学器材盒
CN305535832S (zh) 垃圾桶(zl-001)
CN305536801S (zh) 游戏键盘鼠标转换器
CN305534749S (zh) 锅煲(福猫)
CN305586241S (zh) 汽车散热器格栅
CN305590638S (zh) 沙发架(6688)
CN305531203S (zh) 锁架
CN305583102S (zh) 黑板灯(1)
CN305527135S (zh) 弹力护腕手套

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260807